Halozyme Therapeutics Inc HALO
News
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme to Report Third Quarter 2026 Financial and Operating Results
Halozyme Wins Injunction Against Merck in Keytruda Patent Case — Update
Halozyme Granted Another Injunction Against Merck in Keytruda Patent Case
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Halozyme to Participate at Upcoming Investor Conferences
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case — Update
Correction to Halozyme Granted Injunction Against Merck & Co. Article

